Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Clin. biomed. res ; 43(1): 47-57, 2023.
Article in Portuguese | LILACS | ID: biblio-1435954

ABSTRACT

A fibromialgia é uma síndrome complexa com alterações nociplásticas, caracterizadas por hiperalgesia e alodinia, frequentemente acompanhada pela presença de dor orofacial. Estudos têm demonstrado alta prevalência de disfunção temporomandibular (DTM) em pacientes fibromiálgicos, como fator etiológico ou agravante. O objetivo desta revisão de literatura foi identificar os mecanismos modulatórios comuns à fibromialgia e à DTM, e identificar diferentes modalidades de tratamento para os pacientes fibromiálgicos. Foram utilizados 69 artigos dos últimos 5 anos, além de 4 artigos conceituais anteriores a este período. Identificou-se que os principais fármacos utilizados para os sintomas de fibromialgia são pregabalina, amitriptilina, antidepressivos duais, tramadol, baixas doses de naltrexona e canabinoides. A associação de fármacos pode ser útil para aumentar a eficácia do tratamento e reduzir as doses dos mesmos. Por outro lado, novas terapias não farmacológicas, como as técnicas modulatórias não-invasivas, surgem como opções promissoras, promovendo alterações neuroplásticas importantes no tratamento. Conclusão: Há diversas opções terapêuticas farmacológicas e não-farmacológicas disponíveis no tratamento do paciente fibromiálgico para o especialista em DTM. Portanto, a combinação de diferentes abordagens pode auxiliar na obtenção de um protocolo individualizado, adequado às necessidades do paciente.


Fibromyalgia is a complex syndrome with nociplastic changes, characterized by hyperalgesia and allodynia, often accompanied by the presence of orofacial pain. Studies have shown a high prevalence of temporomandibular disorders (TMD) in fibromyalgia patients, as an etiological or aggravating factor. The aim of this review was to identify the modulatory mechanisms common to fibromyalgia and TMD, and to identify different treatment modalities for fibromyalgia patients. 69 articles from the last five years were included, in addition to 4 conceptual articles prior to this date. The main drugs used for fibromyalgia symptoms are pregabalin, amitriptyline, dual antidepressants, tramadol, low-dose naltrexone and cannabinoids. The combination of drugs may be useful in improving treatment efficacy and for reducing the drug's dose. On the other hand, new non-pharmacological therapies, such as non-invasive modulatory techniques, appear as promising options for treatment, promoting important neuroplastic alterations. Conclusion: Several pharmacological and non-pharmacological therapeutic alternatives are available for specialists in TMD. Therefore, combining therapy approaches can help create individualized protocols that are more effective at meeting the demands of fibromyalgia patients.


Subject(s)
Temporomandibular Joint Disorders/drug therapy , Temporomandibular Joint Disorders/therapy , Fibromyalgia/drug therapy , Fibromyalgia/therapy
2.
Article in Portuguese | LILACS, CONASS, ColecionaSUS, SES-GO | ID: biblio-1358039

ABSTRACT

Tecnologia: Pregabalina, drogas não-opioides disponíveis no SUS, treinamento físico no solo ou em meio aquático. Indicação: Tratamento da fibromialgia. Pergunta: Há diferenças de eficácia e segurança entre a Pregabalina e as outras drogas não opioides ou terapias disponíveis no SUS para tratamento da dor crônica relacionada à fibromialgia? Métodos: Levantamento bibliográfico foi realizado nas bases eletrônicas PUBMED e Cochrane Database, seguindo estratégias de buscas predefinidas, com busca adicional na página eletrônica da Comissão Nacional de Incorporação de Tecnologias em Saúde. Avaliou-se a qualidade metodológica das revisões sistemáticas com Assessing the Methodological Quality of Systematic Reviews versão 2 (AMSTAR-II). Resultados: Foram selecionadas e incluídas 6 revisões sistemáticas. Conclusão: A afirmação de eficácia da Gabapentina, Amitriptilina e Memantina para tratamento da fibromialgia é pouco confiável, pois as evidências são de nível 3, provenientes de ensaios clínicos de baixa qualidade metodológica. Pregabalina é eficaz para reduzir a dor em curto prazo (risco absoluto é 50%, nível 1 de evidência), mas não em longo prazo. O treinamento físico, relatado como única estratégia eficaz para tratamento da fibromialgia nas diretrizes do SUS, não tem efeito clinicamente importante sobre a dor


Technology: Pregabalin, non-opioid drugs available in Brazilian Public Health System, aquatic exercise or exercise on land. Indication: Treatment of fibromyalgia. Question: Are there differences in efficacy and safety between Pregabalin and other non-opioid drugs or therapies available in the SUS for the treatment of chronic pain related to fibromyalgia? Methods: A bibliographic survey was carried out in the electronic databases PUBMED and Cochrane Database, following pre-defined search strategies, with an additional search on the website of the National Commission for the Incorporation of Health Technologies. The methodological quality of systematic reviews was evaluated with Assessing the Methodological Quality of Systematic Reviews version 2 (AMSTAR-II). Results: Six systematic reviews were selected and included. Conclusion: There is not confidence about effectiveness of Gabapentin, Amitriptyline and Memantine for fibromyalgia treatment (level 3 of evidence, from clinical trials of low methodological quality). Pregabalin, in the short term, is effective for reducing pain (absolut risk is 50%, level 1 of evidence), but not in the long term. Physical training, reported as the only effective strategy for treating fibromyalgia in Brazilian Public Health System guidelines, has no clinically important effect on pain.


Subject(s)
Humans , Exercise , Memantine/therapeutic use , Fibromyalgia/drug therapy , Pregabalin/therapeutic use , Gabapentin/therapeutic use , Amitriptyline/therapeutic use , Efficacy , Analgesics, Non-Narcotic
3.
Adv Rheumatol ; 60: 35, 2020. tab, graf
Article in English | LILACS | ID: biblio-1130787

ABSTRACT

Abstract Background: Duloxetine and amitriptyline are antidepressants used in the treatment of fibromyalgia. In published systematic reviews, there is no agreement about which drug is more effective and safer. This study aimed to compare evidence of the efficacy and safety of duloxetine compared with amitriptyline in the treatment of adult patients with fibromyalgia. This work contributes to guiding clinicians on the use of duloxetine or amitriptyline for the treatment of fibromyalgia and provides information for public health decision-makers. Methods: Overview of systematic reviews of clinical trials comparing duloxetine and amitriptyline in the treatment of fibromyalgia. The reviews were screened in Cochrane, PubMed, EMBASE, and SRDR with no restrictions on language and year of publication, considering that the research was conducted in July 2018 and updated until May 2020. The selection was based on the following criteria: adult patients with a diagnosis of fibromyalgia treated with duloxetine or amitriptyline, comparing the efficacy and safety in pain, fatigue, sleep, and mood disorder symptoms and quality of life, in addition to the acceptability of these antidepressants. The methodological quality and strength of evidence were assessed using the AMSTAR and GRADE instruments. Results: Eight systematic reviews were selected. Amitriptyline had low evidence for pain, moderate evidence for sleep and fatigue, and high evidence for quality of life. Duloxetine had high quality of evidence in patients with mood disorders. With low evidence, duloxetine has higher acceptability, but is safer in older patients, while amitriptyline is safer for non-elderly individuals. Conclusion: Both antidepressants are effective in the treatment of fibromyalgia, differing according to the patient's symptoms and profile. Registration: PROSPERO: CRD42019116101.(AU)


Subject(s)
Humans , Fibromyalgia/drug therapy , Duloxetine Hydrochloride/therapeutic use , Amitriptyline/therapeutic use , Quality of Life , Treatment Outcome
4.
Adv Rheumatol ; 60: 09, 2020. tab, graf
Article in English | LILACS | ID: biblio-1088656

ABSTRACT

Abstract Background: EpiFibro (Brazilian Epidemiological Study of Fibromyalgia) was created to study patients with fibromyalgia (FM). Patients were included since 2011 according to the classification criteria for FM of the American College of Rheumatology of 1990 (ACR1990). Objective: To analyze the therapeutic measures prescribed by Brazilian physicians. Materials and methods: Cross-sectional study of a multicenter cohort. The therapeutic measures were described using descriptive statistics. Results: We analyzed 456 patients who had complete data in the registry. The mean age was 54.0 ± 11.9 years; 448 were women (98.2%). Almost all patients (98.4%) used medications, 62.7% received health education, and less than half reported practicing physical exercise; these modalities were often used in combination. Most patients who practiced exercises practiced aerobic exercise only, and a significant portion of patients combined it with flexibility exercises. The most commonly used medication was amitriptyline, followed by cyclobenzaprine, and a minority used medication specifically approved for FM, such as duloxetine and pregabalin, either alone or in combination. Combinations of two or three medications were observed, with the combination of fluoxetine and amitriptyline being the most frequent (18.8%). Conclusion: In this evaluation of the care of patients with FM in Brazil, it was found that the majority of patients are treated with a combination of pharmacological measures. Non-pharmacological methods are underused, with aerobic exercise being the most commonly practiced exercise type. The most commonly prescribed single drug was amitriptyline, and the most commonly prescribed combination was fluoxetine and amitriptyline. Drugs specifically approved for FM are seldom prescribed.(AU)


Subject(s)
Humans , Fibromyalgia/drug therapy , Fibromyalgia/therapy , Records , Fluoxetine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Physical Therapy Modalities , Drug Combinations , Pregabalin/therapeutic use , Duloxetine Hydrochloride/therapeutic use , Amitriptyline/therapeutic use
5.
Rev. cuba. reumatol ; 21(2): e93, mayo.-ago. 2019.
Article in Spanish | LILACS, CUMED | ID: biblio-1093821

ABSTRACT

Introducción: resulta de notable significación el hecho de enfatizar en la difusión de los avances en el tratamiento de la fibromialgia, ya que en décadas precedentes, ha ido alcanzando cada vez mayor magnitud hasta devenir hoy en una problemática de salud pública de atención prioritaria. Objetivo: reportar los avances en el tratamiento de la fibromialgia. Desarrollo: diversos factores pueden exponer esta situación: la elevada incidencia de la fibromialgia en la población general adulta; el escaso conocimiento de su origen y los componentes que la causan; así como el no hallazgo de tratamiento curativo, la inconformidad de los casos y los profesionales en el tratamiento actual del síndrome. Conclusiones: no existen evidencias de que el tratamiento farmacológico de la fibromialgia resulte más efectivo que el no farmacológico, de ahí la notable importancia de estudios como el presente(AU)


Introduction: it is of remarkable significance to emphasize the diffusion of advances in the treatment of fibromyalgia, since in previous decades, it has been reaching ever greater magnitude until becoming today a priority public health problem. Objective: To report the advances in the treatment of fibromyalgia. Development : Several factors can expose this situation: the high incidence of fibromyalgia in the general adult population; the limited knowledge of its origin and the components that cause it; as well as the non-discovery of curative treatment, the nonconformity of cases and professionals in the current treatment of the syndrome. Conclusions: There is no evidence that the pharmacological treatment of fibromyalgia is more effective than the non-pharmacological treatment, hence the remarkable importance of studies such as the present one(AU)


Subject(s)
Humans , Male , Female , Fibromyalgia/therapy , Fibromyalgia/drug therapy , Ecuador
6.
West Indian med. j ; 68(2): 142-148, 2019. graf
Article in English | LILACS | ID: biblio-1341848

ABSTRACT

ABSTRACT Objective: It has been reported that phosphodiesterase-5 (PDE-5) inhibitors improve kidney function during acute and chronic renal failure. This study aimed to determine the possible therapeutic effects of tadalafil, a specific PDE-5 inhibitor, on renal fibrosis induced by unilateral ureteral obstruction (UUO). Methods: Male Sprague-Dawley rats were used and randomly divided into three groups (n = 6) as sham-operated, UUO and tadalafil-treated (10 mg/72 hours, ig) UUO (UUO+T) groups. Unilateral ureteral obstruction was induced by complete ligation of the left ureter and 14 days after surgery creatinine clearance, urinary cyclic guanosine monophosphate (cGMP), renal alpha-smooth muscle actin (α-sma) and transforming growth factor βeta (TGF-β) levels, as well as histologic changes, were observed in all the animals. Results: Unilateral ureteral obstruction-induced renal fibrosis was confirmed by increased α-sma level, collagen deposition, tubular dilation, inflammatory cell infiltration and necrosis. An increased renal TGF-β level and decreased urinary cGMP level was also observed in obstructed animals in addition to reduced creatinine clearance. Tadalafil treatment, which restored the animals 'urinary cGMP level, significantly attenuated the fibrotic changes and TGF-β increase in their kidneys. Conclusion: This study suggests that tadalafil treatment ameliorates renal fibrosis by reducing TGF-β expression and may have important clinical relevance since tadalafil is currently used clinically to treat erectile dysfunction and pulmonary hypertension.


RESUMEN Objetivo: Se ha reportado que los inhibidores de la fosfodiesterasa-5 (PDE-5) mejoran las funciones renales durante la insuficiencia renal aguda y crónica. Este estudio tuvo por objetivo determinar los posibles efectos terapéuticos del tadalafil - un inhibidor específico de la PDE-5 - sobre la fibrosis renal inducida por una obstrucción ureteral unilateral (OUU). Métodos: Se utilizaron ratas machos Sprague-Dawley, divididas de manera aleatoria en tres grupos (n = 6): operación simulada, OUU y tratamiento con tadalafil (10 mg/72 horas, IG), y OUU (OUU+T). La obstrucción uretral unilateral fue inducida por una ligadura completa del uréter izquierdo y 14 días después de la cirugía, se observaron niveles de monofosfato de guanosina cíclico (GMP) urinario, alfa-actina de músculo liso (α-SMA), y factor de crecimiento transformante βeta (FCT-β), así como cambios histológicos en todos los animales. Resultados: La fibrosis renal inducida por obstrucción uretral unilateral fue confirmada por un aumento del nivel de α-SMA, deposición de colágeno, dilatación tubular, infiltración de células inflamatorias y necrosis. También se observó un aumento del nivel de FCT-β renal y una disminución del nivel de GMP urinario en los animales con obstrucción, además de una reducción del aclaramiento de la creatinina. El tratamiento con tadalafil, que restauró el nivel de GMP urinario de los animales, atenuó significativamente los cambios fibróticos y el aumento de FCT-β en los riñones. Conclusión: Este estudio sugiere que el tratamiento con tadalafil mejora la fibrosis renal al reducir la expresión de FCT-β y puede tener una importante relevancia clínica por cuanto el tadalafil se usa hoy día clínicamente para tratar la disfunción eréctil y la hipertensión pulmonar.


Subject(s)
Animals , Rats , Renal Agents/pharmacology , Fibromyalgia/drug therapy , Tadalafil/pharmacology , Kidney Diseases/drug therapy , Ureteral Obstruction/complications , Fibromyalgia/etiology , Rats, Sprague-Dawley , Disease Models, Animal , Kidney Diseases/etiology
7.
Rev. medica electron ; 41(1): 196-202, ene.-feb. 2019.
Article in Spanish | CUMED, LILACS | ID: biblio-1023610

ABSTRACT

Introducción: la fibromialgia es una enfermedad que no encuentra prueba orgánica aparente para explicar un dolor intenso y difuso, acompañado por una gran cantidad de síntomas como son: sueño no reparador, fatiga, síntomas de depresión y ansiedad, rigidez por las mañanas, síndrome de colon irritable. Desde el psico- ballet se trabaja con el cuerpo, con el movimiento, y con la expresión. Objetivo: evaluar los efectos a nivel psíquico y emocional del arte en movimiento. Materiales y métodos: se desarrolló un estudio preliminar con un grupo de 27 mujeres diagnosticadas de fibromialgia y en tratamiento farmacológico, de una media de edad de 41 años. Antes de empezar el proceso y al terminarlo se les hicieron varias entrevistas clínicas y se aplicaron diferentes pruebas de evaluación psicológica. Se les aplica el Test STAI de Spielberg, el de Autoestima de Rosenberg y el POMS. Recibieron veinte sesiones de 90 minutos de duración (60 minutos de psico ballet y 30 minutos de técnicas cognitivas), a razón de una sesión semanal durante 5 meses. Resultados: indican reducción de la fatiga, de la ansiedad, de la depresión y de la percepción del dolor y un aumento del vigor, mejora de la autoimagen y de la autoestima. Conclusiones: la actividad físico artística que aporta el psico-ballet mejora la calidad de vida de este tipo de pacientes, fortaleciendo su capacidad de comunicación, mejorando la autoestima y el vigor, reduciendo la fatiga y la percepción del dolor. (AU)


Introduction: fibromyalgia is a disease in which no apparent proof is found to explain an intense diffuse pain accompanied by a great quantity of symptoms like un-restful sleep, fatigue, depression and anxiety, stiffness in the morning, and irritable bowel syndrome. The body, movement and expression are trained using psycho-ballet. Objective: to assess the effects of the art of movement at the psychical and emotional level, paying attention to pain, with the pretension that the patient explore it through his body and his movement in a secure space and accompanied by people in the same situation, what facilitates communication. Material and methods: the study was carried out with a group of 27 women averagely aged 41 years, diagnosed with fibromyalgia under pharmacological treatment. Before the beginning of the treatment, and after finishing it, they answered to several clinical interviews and applied different tests of psychological evaluation: Spielberg´s State-Trait Anxiety Inventory (STAI), Rosenberg's self-steem scale, and mood states profile test. They underwent 20 sessions of 90 minutes (60 minutes of Psycho-ballet and 30 minutes of cognitive techniques), one session weekly during 5 months. Results: patients report the reduction of fatigue, anxiety, depression and pain perception, a vitality increase, and improvement of self-image and self-steem. Conclusions: physic-artistic activity provided by psycho-ballet improves life quality in this kind of patients, strengthens their communication ability, improves self-steem and vitality, and reduces fatigue and pain perception. (AU)


Subject(s)
Humans , Fibromyalgia/diagnosis , Fibromyalgia/therapy , Dance Therapy/methods , Patient Health Questionnaire , Fibromyalgia/psychology , Fibromyalgia/drug therapy , Journal Article
8.
Medwave ; 19(4): e7632, 2019.
Article in English, Spanish | LILACS | ID: biblio-997905

ABSTRACT

INTRODUCCIÓN La fibromialgia es una condición reumática no articular caracterizada por distintos síntomas, donde destacan principalmente el dolor, sensibilidad muscular, fatiga, insomnio, rigidez matinal, depresión y disminución de la funcionalidad cotidiana. Aún no existe claridad respecto de su etiología, pero se ha planteado que la deficiencia de elementos tales como el magnesio podría tener un rol tanto en la fisiopatología de la fibromialgia como también contribuir a sus síntomas clínicos. MÉTODOS Realizamos una búsqueda en Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante el cribado de múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, analizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES Identificamos siete revisiones sistemáticas que en conjunto incluyeron 11 estudios primarios, de los cuales solo uno corresponde a un ensayo aleatorizado. Concluimos que el uso de magnesio y ácido málico en pacientes con fibromialgia tiene poco o nulo impacto en dolor y en los síntomas depresivos.


INTRODUCTION Fibromyalgia is characterized by myalgia and a combination of different symptoms including pain, fatigue, insomnia, morning rigidity, depression and a reduction in every-day functioning. Its aetiology is not clear, but it has been suggested that deficiency in certain minerals such as magnesium may play a role both in the physiopathology and in contributing to the symptoms. METHODS We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS We identified seven systematic reviews which included 11 primary studies of which one was a randomized trial. Our conclusion is that the use of magnesium and malic acid in patients with fibromyalgia makes little or no difference on pain and on depressive symptoms.


Subject(s)
Humans , Fibromyalgia/drug therapy , Magnesium/administration & dosage , Malates/administration & dosage , Fibromyalgia/physiopathology , Randomized Controlled Trials as Topic , Databases, Factual , Dietary Supplements
9.
Evid. actual. práct. ambul ; 21(3): 92-93, oct. 2018.
Article in Spanish | LILACS | ID: biblio-1016268

ABSTRACT

A partir de una viñeta clínica, la autora describe los resultados de dos revisiones sistemáticas que evaluaron la eficacia y la seguridad de la pregabalina para el alivio del dolor en pacientes con fibromialgia. (AU)


Based on a clinical vignette, the author describes the results of two systematic reviews that evaluated the efficacy and safety of pregabalin for pain relief in patients with fibromyalgia. (AU)


Subject(s)
Humans , Female , Adult , Fibromyalgia/drug therapy , Pregabalin/therapeutic use , Pain/prevention & control , Pain/drug therapy , Placebos , Fibromyalgia/diagnosis , Fibromyalgia/etiology , Randomized Controlled Trials as Topic , Pregabalin/administration & dosage , Pregabalin/adverse effects , Systematic Reviews as Topic
10.
Rev. medica electron ; 40(5): 1507-1535, set.-oct. 2018.
Article in Spanish | LILACS, CUMED | ID: biblio-978685

ABSTRACT

RESUMEN La fibromialgia es una enfermedad crónica, definida por dolor generalizado, a menudo acompañado de fatiga y alteraciones del sueño, la cual afecta a uno de cada 20 pacientes en la atención primaria. Aunque la mayoría de los pacientes con fibromialgia se manejan en la atención primaria, el diagnóstico y tratamiento continúan presentando un desafío, y los pacientes se envían a menudo las consultas de otros especialistas. Las investigaciones exhaustivas, la prescripción de múltiples drogas para tratar los diferentes síntomas, los retrasos en el diagnóstico, y el aumento de la invalidez, necesita de un conocimiento más profundo y un tratamiento basado en el médico de la atención primaria. Se hizo una revisión de diferentes publicaciones actualizadas sobre la epidemiología, patofisiología y tratamiento de la fibromialgia aparecidas en PubMed, Scielo, Hinari y Medline, además de artículos pertinentes, hasta comienzos del año 2017, de donde se seleccionaron diferentes artículos en base a la calidad, relevancia e importancia en cuanto a las nuevas directrices de esta enfermedad. La aplicación de novedosos sistemas de diagnóstico y enfrentamiento al dolor crónico aplicable en la atención primaria disminuiría el tiempo de diagnóstico, costosas pruebas, demora en el diagnóstico y mejores resultados terapéuticos en estos pacientes. El tratamiento centrado en el paciente desde la atención necesita de un grupo multidisciplinario con una alta preparación en esta enfermedad. Aunque se mantienen algunas barreras para la aplicación de un sistema de atención médica de la fibromialgia, esto permitiría un cambio muy favorable en el tratamiento de esos pacientes (AU).


ABSTRACT Fibromyalgia is a chronic disorder defined by widespread pain, frequently accompanied by fatigue and sleep disturbance, affecting up to one in 20 patients in the primary care. Although most of the patients with fibromyalgia are managed in the primary care, its diagnosis and treatment are still a challenge and the patients are often referred to the consultation of other specialists. The exhaustive research, the prescription of several drugs to treat the different symptoms, the diagnosis retardation, and the increase of disability, require deeper knowledge and a treatment led by the health professional of the primary care. We reviewed the epidemiology, pathophysiology and management of fibromyalgia by searching PubMed, Scielo, Hinari and Medline, and references from relevant articles published until the beginning of 2017, choosing them on the basis of quality, relevance to the illness and importance in illustrating current management pathways and the potential for future improvements. The implementation of a framework for diagnosis and chronic pain management in the primary care would reduce diagnostic time consumption, costly tests, and diagnostic delays, and will achieve better therapeutic outcomes in these patients. The patient-centred treatment from the primary care needs a multi disciplinary team highly trained in this disease. Although there are still several barriers for the application of a medical care system in fibromyalgia, It would allow a favourable change in the treatment of these patients (AU).


Subject(s)
Humans , Male , Female , Primary Health Care/methods , Fibromyalgia/epidemiology , Patients , Fibromyalgia/diagnosis , Fibromyalgia/prevention & control , Fibromyalgia/drug therapy , Fibromyalgia/rehabilitation , Chronic Disease/drug therapy , Chronic Disease/rehabilitation , Physicians, Primary Care
11.
São Paulo med. j ; 136(5): 472-478, Sept.-Oct. 2018. tab
Article in English | LILACS | ID: biblio-979377

ABSTRACT

ABSTRACT BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach. DESIGN AND SETTING: Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). METHODS: A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed. RESULTS: Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions: neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population. CONCLUSIONS: This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.


Subject(s)
Humans , Cannabinoids/therapeutic use , Systematic Reviews as Topic , Schizophrenia/drug therapy , Vomiting/drug therapy , Fibromyalgia/drug therapy , Tourette Syndrome/drug therapy , HIV Infections/drug therapy , Evidence-Based Medicine/standards , Dementia/drug therapy , Epilepsy/drug therapy , Nausea/drug therapy
12.
Medwave ; 18(1): e7153, 2018.
Article in English, Spanish | LILACS | ID: biblio-910393

ABSTRACT

INTRODUCCIÓN: Se postula que los cannabinoides pudieran tener beneficios en la fibromialgia, sin embargo, su efectividad clínica sigue siendo un tema de discusión. MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos quince revisiones sistemáticas que en conjunto incluyen dos ensayos aleatorizados pertinentes. Concluimos que no está claro si los cannabinoides tienen beneficios en la fibromialgia porque la certeza de la evidencia es muy baja. Por otra parte, están asociados a efectos adversos frecuentes.


INTRODUCTION: Cannabinoids have been proposed as a therapeutic alternative for fibromyalgia. However, their clinical effectiveness is a matter of debate. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified fifteen systematic reviews including two randomized trials overall. We concluded it is not clear whether cannabinoids have any benefit in fibromyalgia because the certainty of the evidence is very low. On the other hand, they are associated to frequent adverse effects.


Subject(s)
Humans , Cannabinoids/therapeutic use , Fibromyalgia/drug therapy , Randomized Controlled Trials as Topic , Databases, Factual , Treatment Outcome
13.
Arq. neuropsiquiatr ; 73(10): 861-866, Oct. 2015. tab, ilus
Article in English | LILACS | ID: lil-761534

ABSTRACT

Objective : The aim was to examine the effect of blocking trigger points in the temporal muscles of patients with masticatory myofascial pain syndrome, fibromyalgia and headache.Method : Seventy patients with one trigger point were randomly divided into 3 groups: injection with saline or anesthetic and non-injected (control).Results : Pain was reduced in 87.71% patients injected with saline and 100% injected with anesthetic. Similar results were obtained for headache frequency. With regard to headache intensity, the injection groups differed from the control group, but not between themselves.Conclusion : Treatment with injection at trigger points decreased facial pain and frequency and intensity of headache. Considering the injected substance there was no difference.


Objetivo : Comparar o efeito terapêutico do bloqueio de pontos-gatilho na musculatura temporal com soro fisiológico e anestésico em pacientes com síndrome da dor miofascial mastigatória, fibromialgia e cefaleia, entre sí e com controles não-infiltrados.Método : Setenta pacientes que apresentaram pelo menos um ponto-gatilho na musculatura temporal foram aleatoriamente divididas em 3 grupos: infiltração com soro fisiológico, infiltração com anestésico e controle (não-infiltradas).Resultados : Houve redução na intensidade de dor na face em 87,71% dos pacientes infiltrados com soro fisiológico e em 100% dos pacientes infiltrados com anestésico, mas não no grupo controle. Houve similaridade dos resultados considerando a frequência da cefaléia. Quanto à intensidade da cefaléia, tanto a infiltração com soro fisiológico, quanto com anestésico foram efetivos e sem diferença significativa entre sí, ao contrário do grupo controle.Conclusões : O tratamento com infiltração diminui a dor na face, bem com a frequência e a intensidade da cefaléia. Quando considerado a substância infiltrada não há diferenças no tratamento.


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Anesthetics, Local/administration & dosage , Fibromyalgia/drug therapy , Headache Disorders/drug therapy , Myofascial Pain Syndromes/drug therapy , Trigger Points , Temporal Muscle/drug effects , Double-Blind Method , Injections, Intramuscular/methods , Pain Measurement , Statistics, Nonparametric , Treatment Outcome
14.
J. bras. med ; 102(6)dez. 2014. graf, ilus, tab, mapas
Article in Portuguese | LILACS | ID: lil-737128

ABSTRACT

A fibromialgia (FM) é uma síndrome de dor difusa crônica acompanhada de sintomas somáticos, tais como fadiga, transtornos do humor, do sono e da cognição. Em uma abordagem prática do paciente com FM, além das medidas não farmacológicas, cada sintoma pode ser tratado com medicamento específico. O objetivo deste artigo é prover revisão atualizada da literatura sobre os principais medicamentos atualmente disponíveis no Brasil para o tratamento da FM em adultos. O sucesso terapêutico da FM depende, essencialmente, do uso racional de medicamentos voltados para os sintomas refratários às medidas não farmacológicas.


Fibromyalgia (FM) is the chronic widespread pain syndrome associated with fatigue, mood, sleep and cognitive disorders. Besides non-pharmacological approach, each symptom should be treated with a specific drug. The goal of this study is to provide up-to-date literature review on main aspects of adult FM drugs available for use in Brazil. Treatment success in FM depends essentially on using drugs based on symptoms that are not responsive to non-pharmacological approach.


Subject(s)
Humans , Fibromyalgia/drug therapy , Tramadol/therapeutic use , Serotonin/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Acetaminophen/therapeutic use , Monoamine Oxidase Inhibitors/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use
15.
J. bras. med ; 101(5): 25-30, set.-out. 2013. ilus, tab
Article in Portuguese | LILACS | ID: lil-706143

ABSTRACT

Fibromialgia (FM) é a síndrome de dor difusa crônica acompanhada de sintomas somáticos, tais como fadiga, transtornos do humor, do sono e da cognição. Em uma abordagem prática do paciente com FM, além das medidas não farmacológicas, cada sintoma pode ser tratado com medicamento específico. Este artigo provê revisão atualizada da literatura sobre os principais medicamentos atualmente disponíveis no Brasil para o tratamento da FM em adultos


Fibromyalgia (FM) is the chronic widespread pain syndrome associated with fatigue, mood, sleep and cognitive disorders. Besides non-pharmacological approach, each symptom should be treated with a specific drug. The goal of this study is to provide up-to-date literature review on main aspects of adult FM drugs available for use in Brazil


Subject(s)
Humans , Male , Female , Adult , Fibromyalgia/physiopathology , Fibromyalgia/drug therapy , Analgesics, Opioid/therapeutic use , Analgesics/therapeutic use , Anticonvulsants/therapeutic use , Antidepressive Agents/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Drug Utilization , Pain/drug therapy , Muscle Relaxation
16.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 35(1): 21-28, Mar. 2013. ilus, tab
Article in English | LILACS | ID: lil-670469

ABSTRACT

The purpose of the study was to evaluate the efficacy of an extract of Panax ginseng in patients with fibromyalgia. A randomized, double-blind, controlled clinical trial was carried out over 12 weeks to compare the effects of P. ginseng (100 mg/d) with amitriptyline (25 mg/d) and placebo in 38 patients with fibromyalgia: 13 in Group I (amitriptyline), 13 in Group II (placebo), and 12 in Group III (P. ginseng). Ratings on the Visual Analogue Scale (VAS) revealed a reduction in pain in the P. ginseng group (p < .0001), an improvement in fatigue (p < .0001) and an improvement in sleep (p < .001), with respect to baseline characteristics, but there were no differences between the three groups. With respect to anxiety, improvements occurred in the P. ginseng group compared to baseline (p < .0001); however, amitriptyline treatment resulted in significantly greater improvements (p < .05). P. ginseng reduced the number of tender points and improved patients' quality of life (using the Fibromyalgia Impact Questionnaire - FIQ); however, there were no differences between groups. The beneficial effects experienced by patients for all parameters suggest a need for further studies to be performed on the tolerability and efficacy of this phytotherapic as a complementary therapy for fibromyalgia.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Amitriptyline/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Fibromyalgia/drug therapy , Panax , Plant Extracts/therapeutic use , Double-Blind Method , Fibromyalgia/physiopathology , Pain Measurement , Quality of Life , Surveys and Questionnaires , Time Factors , Treatment Outcome
18.
Oman Medical Journal. 2012; 27 (3): 192-195
in English | IMEMR | ID: emr-144377

ABSTRACT

Fibromyalgia Syndrome [FMS] is a chronic condition causing pain, stiffness, and tenderness of the muscles, tendons, and joints. It is also characterized by restless sleep, tiredness, fatigue, anxiety, depression, and disturbances in bowel functions. The etiology of fibromyalgia remains unknown, but recent advances and discoveries have helped to unravel some of the mysteries of this disease. Research highlights some of the biochemical, metabolic, and immunoregulatory abnormalities associated with fibromyalgia. Management of FMS at the present time is very difficult as it has multiple etiological factors and psychological predispositions; however, a patient centered approach is essential to handle this problem


Subject(s)
Humans , Fibromyalgia/diagnosis , Disease Management , Syndrome , Quality of Life , Fibromyalgia/drug therapy , Fibromyalgia/therapy
19.
In. Montes, María José; Retamoso, Irene; Vázquez, Cristina. El dolor: un abordaje interdisciplinario. Montevideo, Zona, 2012. p.476-496.
Monography in Spanish | UY-BNMED, BNUY, LILACS | ID: biblio-1519466
20.
Rev. bras. odontol ; 64(1/2): 94-97, 2007. tab
Article in Portuguese | LILACS, BBO | ID: lil-541861

ABSTRACT

Uma das técnicas mais efetivas para inativação do ponto-gatilho (PG) na Síndrome da Dor Miofacial é o agulhamento. Em vista disso, o objetivo deste trabalho foi, através de uma revisão da literatura pertinente, comparar dois tipos de terapia com agulhamento, seco ou com injeção de substâncias, com a finalidade de identificar a mais eficiente com relação à inativação de ponto-gatilho nas regiões da cabeça e pescoço. Ao consultar trabalhos publicados na literatura entre 1994 e 2006, pôde-se concluir que não houve diferenças quanto ao resultado final, sendo ambas as técnicas eficazes.


Subject(s)
Fibromyalgia/drug therapy , Fibromyalgia/therapy , Review Literature as Topic
SELECTION OF CITATIONS
SEARCH DETAIL